Caseware UK (AP4) 2022.0.179 2022.0.179 2023-06-302023-06-30false2022-07-010falseNo description of principal activity0true 04773064 2022-07-01 2023-06-30 04773064 2021-07-01 2022-06-30 04773064 2023-06-30 04773064 2022-06-30 04773064 c:CompanySecretary1 2022-07-01 2023-06-30 04773064 c:Director1 2022-07-01 2023-06-30 04773064 c:Director5 2022-07-01 2023-06-30 04773064 c:RegisteredOffice 2022-07-01 2023-06-30 04773064 d:CurrentFinancialInstruments 2023-06-30 04773064 d:CurrentFinancialInstruments 2022-06-30 04773064 d:CurrentFinancialInstruments d:WithinOneYear 2023-06-30 04773064 d:CurrentFinancialInstruments d:WithinOneYear 2022-06-30 04773064 d:ShareCapital 2023-06-30 04773064 d:ShareCapital 2022-06-30 04773064 d:RetainedEarningsAccumulatedLosses 2022-07-01 2023-06-30 04773064 d:RetainedEarningsAccumulatedLosses 2023-06-30 04773064 d:RetainedEarningsAccumulatedLosses 2022-06-30 04773064 c:OrdinaryShareClass1 2022-07-01 2023-06-30 04773064 c:OrdinaryShareClass1 2023-06-30 04773064 c:FRS102 2022-07-01 2023-06-30 04773064 c:Audited 2022-07-01 2023-06-30 04773064 c:FullAccounts 2022-07-01 2023-06-30 04773064 c:PrivateLimitedCompanyLtd 2022-07-01 2023-06-30 04773064 c:SmallCompaniesRegimeForAccounts 2022-07-01 2023-06-30 xbrli:shares iso4217:GBP xbrli:pure
Registered number: 04773064


DEL LABORATORIES U.K. LIMITED
FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2023

 
DEL LABORATORIES U.K. LIMITED
 
 
COMPANY INFORMATION


Directors
M Hosenbokus 
F Fowler 




Company secretary
M Hosenbokus



Registered number
04773064



Registered office
Eureka Science Park

Ashford

Kent

TN25 4AQ




Independent auditors
Xeinadin Audit Limited
Chartered Accountants & Statutory Auditor

8th Floor

Becket House

36 Old Jewry

London

EC2R 8DD




Accountants
Elman Wall Limited
8th Floor

Becket House

36 Old Jewry

London

EC2R 8DD





 
DEL LABORATORIES U.K. LIMITED
 

CONTENTS



Page
Statement of Financial Position
1
Notes to the Financial Statements
2 - 3


 
DEL LABORATORIES U.K. LIMITED
REGISTERED NUMBER: 04773064

STATEMENT OF FINANCIAL POSITION
AS AT 30 JUNE 2023

2023
2022
Note
£
£

  

  

Creditors: amounts falling due within one year
 4 
(2,027,530)
(1,984,894)

Net current liabilities
  
 
 
(2,027,530)
 
 
(1,984,894)

  

Net liabilities
  
(2,027,530)
(1,984,894)


Capital and reserves
  

Called up share capital 
 5 
2
2

Profit and loss account
 6 
(2,027,532)
(1,984,896)

  
(2,027,530)
(1,984,894)


The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities.

The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The Company has opted not to file the statement of comprehensive income in accordance with provisions applicable to companies subject to the small companies' regime.

The financial statements were approved and authorised for issue by the board and were signed on its behalf by: 




M Hosenbokus
Director

Date: 1 November 2023

The notes on pages 2 to 3 form part of these financial statements.

Page 1

 
DEL LABORATORIES U.K. LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2023

1.


General information

Del Laboratories U.K. Limited is a private company limited by shares incorporated in England and Wales, United Kingdom.
The address of the registered office is given in the Company Information page of these financial statements.
The Company did not trade during the year. 

2.Accounting policies

 
2.1

Basis of preparation of financial statements

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with Section 1A of Financial Reporting Standard 102, the Financial Reporting Standard applicable in the UK and the Republic of Ireland and the Companies Act 2006.

  
2.2

Going concern

The parent company, Coty Inc, has indicated its willingness and intention to provide ongoing support to the Company. Having considered this, the directors are confident that the Company will continue to receive support from its parent for a period of at least twelve months from the signing of the financial statements.
On this basis, the directors consider it appropriate to prepare the financial statements on a going concern basis.

 
2.3

Finance costs

Finance costs are charged to profit or loss over the term of the debt using the effective interest method so that the amount charged is at a constant rate on the carrying amount. Issue costs are initially recognised as a reduction in the proceeds of the associated capital instrument.

 
2.4

Creditors

Short-term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.


3.


Employees

The Company has no employees other than the directors, who did not receive any remuneration (2022 - £NIL).


4.


Creditors: Amounts falling due within one year

2023
2022
£
£

Amounts owed to group undertakings
2,027,530
1,984,894


Page 2

 
DEL LABORATORIES U.K. LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2023

5.


Share capital

2023
2022
£
£
Allotted, called up and fully paid



2   Ordinary shares of £1.00 each
2
2



6.


Reserves

Profit and loss account

Profit and loss includes all current and prior periods retained profits and losses. 


7.


Related party transactions

The company has taken advantage of the exemption under FRS 102 from disclosing transactions with other wholly-owned group-members. There are no other related party transactions. 


8.


Controlling party

The directors regard Coty Inc. as the Company’s ultimate controlling party. 


9.


Auditors' information

The auditors' report on the financial statements for the year ended 30 June 2023 was unqualified.

The audit report was signed on 1 November 2023 by Yasin Khandwalla FCCA (Senior Statutory Auditor) on behalf of Xeinadin Audit Limited.

 
Page 3